418 related articles for article (PubMed ID: 11155094)
1. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
[TBL] [Abstract][Full Text] [Related]
2. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
3. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
[TBL] [Abstract][Full Text] [Related]
4. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
[TBL] [Abstract][Full Text] [Related]
5. The use of long-acting somatostatin analogues in acromegaly.
Jenkins PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S111-4. PubMed ID: 10984265
[TBL] [Abstract][Full Text] [Related]
6. A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
Turner HE; Vadivale A; Keenan J; Wass JA
Clin Endocrinol (Oxf); 1999 Sep; 51(3):275-80. PubMed ID: 10469005
[TBL] [Abstract][Full Text] [Related]
7. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
[TBL] [Abstract][Full Text] [Related]
10. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
11. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
12. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.
Caron P; Tabarin A; Cogne M; Chanson P; Jaquet P
Eur J Endocrinol; 2000 Jun; 142(6):565-71. PubMed ID: 10822218
[TBL] [Abstract][Full Text] [Related]
13. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
Murray RD; Melmed S
J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
[TBL] [Abstract][Full Text] [Related]
14. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
al-Maskari M; Gebbie J; Kendall-Taylor P
Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
[TBL] [Abstract][Full Text] [Related]
16. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
17. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
[TBL] [Abstract][Full Text] [Related]
19. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]